Cambridge R&D Tax Credit Benefits for Corporations

R&D Tax Credits for Cambridge, Massachusetts Businesses

Cambridge, Massachusetts, is known for its strong presence in healthcare, education, technology, and retail. Top companies in the city include Mount Auburn Hospital, a major healthcare provider; Harvard University, a key educational institution; MIT, a prominent technology company; Walmart, a global retail giant; and Amazon, a global logistics and e-commerce company. The R&D Tax Credit can help these industries reduce tax liabilities, encourage innovation, and enhance business performance. By utilizing the R&D Tax Credit, companies can reinvest savings into advanced research driving growth and competitiveness in Cambridge’s economy.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 6 Liberty Square, Boston, Massachusetts is less than 6 miles away from Cambridge and provides R&D tax credit consulting and advisory services to Cambridge and the surrounding areas such as: Boston, Worcester, Providence, Springfield and Bridgeport.

If you have any questions or need further assistance, please call or email our local Massachusetts Partner on (857) 347-5915.
Feel free to book a quick teleconference with one of our Massachusetts R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Cambridge, Massachusetts Patent of the Year – 2024/2025

STRM.bio Incorporated has been awarded the 2024/2025 Patent of the Year for their groundbreaking ‘Compositions and methods related to megakaryocyte-derived extracellular vesicles’. Their invention, detailed in U.S. Patent No. 12090234, this innovation leverages naturally occurring extracellular vesicles (EVs) from megakaryocytes – platelet-producing cells – to deliver gene therapies directly to bone marrow stem cells.

Unlike traditional gene delivery methods, which often rely on viral vectors or lipid nanoparticles, STRM.bio’s approach utilizes megakaryocyte-derived EVs as a non-viral, off-the-shelf delivery system. These EVs are engineered to carry therapeutic cargo, such as DNA or RNA, and are capable of targeting hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. This targeted delivery minimizes off-target effects and enhances the precision of gene therapies.

Preclinical studies in mice and non-human primates have demonstrated that these EVs preferentially accumulate in the bone marrow following intravenous administration, with minimal distribution to other organs like the liver or spleen. Importantly, the platform has shown no adverse effects on platelet counts, coagulation parameters, or liver and kidney function, indicating its safety for repeated dosing.

STRM.bio’s patented technology represents a significant advancement in gene therapy, offering a safer, more efficient method for treating rare blood disorders and potentially other diseases requiring targeted gene delivery.